Knox accuses media of having built false story around her

1 / 2
US journalist Amanda Knox reacts after she addressed a panel discussion titled "Trial by Media" during the Criminal Justice Festival at the Law University of Modena, northern Italy on June 15, 2019. (AFP)
2 / 2
US journalist Amanda Knox cries as she addresses a panel discussion titled "Trial by Media" during the Criminal Justice Festival at the Law University of Modena, northern Italy on June 15, 2019. (AFP)
Updated 16 June 2019

Knox accuses media of having built false story around her

  • Knox said she came back to Italy despite the fact that she was afraid of being “molested, derided, framed, that new accusations will be directed against me for telling my truth”

ROME: Taking the stage Saturday at an Italian conference on justice, Amanda Knox accused the media of having built a false narrative around her during her yearslong murder trial and appeals process, depicting her as guilty even though she was eventually acquitted.
The former exchange student from the United States who became the focus of a sensational murder case returned to Italy this week for the first time since an appeals court acquitted her in 2011 in the slaying of her British roommate, Meredith Kercher.
Knox, speaking in Italian on a panel discussion at the Criminal Justice Festival in Modena titled “Trial by media,” said she was depicted “on the global scene as cunning, psychopath, drug-addicted, whore. Guilty.”
Speaking through tears, she said the media that labelled her “Foxy Knoxy” invented a “false and baseless story, which fueled people’s fantasies and talked to their fears.”
Knox’s 2011 acquittal was part of a long legal process that saw multiple flip-flop rulings before she was definitively acquitted in 2015 by Italy’s highest court.
Knox said she came back to Italy despite the fact that she was afraid of being “molested, derided, framed, that new accusations will be directed against me for telling my truth.”
She also criticized Italian prosecutors, who described a scenario made up of “orgies and sex toys” during her first trial, even though that version of the story was toned down in the appeal.
Knox acknowledged that despite her final acquittal “I remain a controversial figure in the public opinion, especially here in Italy.”
She had been accused with her Italian boyfriend at the time, Raffaele Sollecito, and Ivorian-born Rudy Guede of killing Kercher on Nov. 1, 2007, in the university town of Perugia. After multiple rulings, Italy’s highest court definitively acquitted Knox and Sollecito in 2015. Guede is still serving a 16-year sentence.
During her speech, which was followed by a standing ovation, Knox recalled Perugia prosecutor Giuliano Mignini as the one who accused her in his search for justice.
“One day I’d like to meet the real Mignini, and I hope that when he comes, he will also see that I am not a monster, I simply am Amanda,” Knox said.
On Friday, the lawyer for Kercher’s family described Knox’s invitation to speak at the Criminal Justice Festival as “inappropriate.”
“Inviting her to a technical panel on justice was a mistake,” Francesco Maresca told The Associated Press, adding that “lawyers for both parts should have been involved.”


Indonesia begins human trials of anti-virus vaccine

Updated 12 August 2020

Indonesia begins human trials of anti-virus vaccine

  • The third phase of the clinical trials of the vaccine — which is manufactured by China’s Sinovac Biotech in collaboration with its Indonesian pharma counterpart, Bio Farma — began on Tuesday
  • The third phase is a must before the vaccine, known as CoronaVac, goes into the production stage and is a prerequisite for all pharmaceutical products, including medicines and vaccines

JAKARTA: Indonesia is stepping up efforts to find a COVID-19 vaccine by launching human trials of a potentially effective drug amid criticism of its lacklustre handling of the pandemic and concerns about its plummeting economy.

The third phase of the clinical trials of the vaccine — which is manufactured by China’s Sinovac Biotech in collaboration with its Indonesian pharma counterpart, Bio Farma — began on Tuesday and is being conducted by the Padjadjaran University School of Medicine at six locations in Bandung, West Java province, where the university and the state-owned pharma company are based.

“The first day of the trial went well, with 20 volunteers in each of the six locations injected with the potential vaccine. We have no complaints so far, and we are preparing the second injection batch on Aug 14,” Iwan Setiawan, a spokesman for Bio Farma, told Arab News on Wednesday.

He added that the six-month trial would require the participation of 1,620 volunteers who were “in good health and had not tested positive” for the disease.

Ridwan Kamil, governor of West Java, Indonesia’s most populated province, is among the volunteers who have signed up for the trial.

The third phase is a must before the vaccine, known as CoronaVac, goes into the production stage and is a prerequisite for all pharmaceutical products, including medicines and vaccines.

“The potential vaccine had gone through three trials; the pre-clinical, the clinical trial first phase and the second phase in China,” Bio Farma CEO Honesti Basyir said in a statement.

According to Basyir, Sinovac is one of the few institutions that have progressed to the third phase of the clinical trial from among hundreds of research institutions around the world that are developing the COVID-19 vaccine.

According to Oxford Business Group’s COVID-10 Economic Impact Assessment, there are more than 150 different vaccines that international researchers are working on. However, only 26 have reached the human trial stage so far.

Once the trials are concluded, Bio Farma will register the vaccine with the Food and Drug Supervisory Agency so that it can begin mass-production of the drug.

“We have prepared a production facility for the COVID-19 vaccine with a maximum capacity of 100 million dosages, and by the end of December this year we will have an increased production capacity to produce an additional 150 million dosages,” Basyir said.

President Joko Widodo oversaw the first injections to the batch of volunteers in one of the six locations and also toured Bio Farma’s production facility. 

“We hope this clinical trial would conclude in six months and so we can start producing the vaccine in January and vaccinate our people soon,” Widodo said.

State-Owned Enterprise Minister Erick Thohir, who is also the head of the COVID-19 mitigation and national economic recovery committee, said that Bio Farma was a well-established vaccine producer whose products were halal-compliant and used in 150 countries, including in the Middle East.

The collaboration with Sinovac is one of three vaccine-development projects that Indonesia is engaging in with foreign parties as it grapples with a surge in infections. At the same time, social restrictions and economic activities were eased. The other two projects are with South Korea’s Genexine and Norway’s Coalition for Epidemic, Preparedness and Innovation.

As of Wednesday, Indonesia had reported 130,718 infections with 1,942 new cases, 85,798 recoveries and 5,903 deaths, although experts suggest that the numbers could be higher due to the country’s low testing capacity.

Cases also surged in the capital Jakarta with workplaces emerging as the new infection clusters after thousands of employees returned to work recently.